다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Cellular signalling, v.41, 2018년, pp.89 - 96
Chen, Wei (Corresponding author.) , Mook Jr., Robert A. , Premont Jr., Richard T. , Wang Jr., Jiangbo
AI-Helper
Abstract Niclosamide is an oral antihelminthic drug used to treat parasitic infections in millions of people worldwide. However recent studies have indicated that niclosamide may have broad clinical applications for the treatment of diseases other than those caused by parasites. These diseases and ...
1 Andrews P. Thyssen J. Lorke D. The biology and toxicology of molluscicides, Bayluscide Pharmacol. Ther. 19 1983 245 295
2 Pearson R.D. Hewlett E.L. Niclosamide therapy for tapeworm infections Ann. Intern. Med. 102 1985 550 551 3977200
3 WHO The Selection and Use of Essential Medicines 2007 World Health Organization Geneva
4 Weinbach E.C. Garbus J. Mechanism of action of reagents that uncouple oxidative phosphorylation Nature 221 1969 1016 4180173
5 Williamson R.L. Metcalf R.L. Salicylanilides: a new group of active uncouplers of oxidative phosphorylation Science 158 1967 1694 1695 (New York, N.Y.) 4228706
6 Frayha G.J. Smyth J.D. Gobert J.G. Savel J. The mechanisms of action of antiprotozoal and anthelmintic drugs in man Gen. Pharmacol. 28 1997 273 299 9013207
7 Swan G.E. The pharmacology of halogenated salicylanilides and their anthelmintic use in animals J. S. Afr. Vet. Assoc. 70 1999 61 70 10855824
8 Kebebew E. Reiff E. Duh Q.Y. Clark O.H. McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J. Surg. 30 2006 872 878 16680602
9 Satoh K. Zhang L. Zhang Y. Chelluri R. Boufraqech M. Nilubol N. Patel D. Shen M. Kebebew E. Identification of Niclosamide as a novel anticancer agent for adrenocortical carcinoma Clin. Cancer Res. 22 2016 3458 3466 26873959
10 Donepudi M.S. Kondapalli K. Amos S.J. Venkanteshan P. Breast cancer statistics and markers J. Cancer Res. Ther. 10 2014 506 511 25313729
11 Lu W. Lin C. Roberts M.J. Waud W.R. Piazza G.A. Li Y. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway PLoS One 6 2011 e29290
12 Londono-Joshi A.I. Arend R.C. Aristizabal L. Lu W. Samant R.S. Metge B.J. Hidalgo B. Grizzle W.E. Conner M. Forero-Torres A. Lobuglio A.F. Li Y. Buchsbaum D.J. Effect of niclosamide on basal-like breast cancers Mol. Cancer Ther. 13 2014 800 811 24552774
13 Fonseca B.D. Diering G.H. Bidinosti M.A. Dalal K. Alain T. Balgi A.D. Forestieri R. Nodwell M. Rajadurai C.V. Gunaratnam C. Tee A.R. Duong F. Andersen R.J. Orlowski J. Numata M. Sonenberg N. Roberge M. Structure-activity analysis of Niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of Rapamycin Complex 1 (mTORC1) signaling J. Biol. Chem. 287 2012 17530 17545 22474287
14 Kim S.Y. Kang J.W. Song X. Kim B.K. Yoo Y.D. Kwon Y.T. Lee Y.J. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells Cell. Signal. 25 2013 961 969 23333246
15 Ren X. Duan L. He Q. Zhang Z. Zhou Y. Wu D. Pan J. Pei D. Ding K. Identification of Niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway ACS Med. Chem. Lett. 1 2010 454 459 24900231
16 Wang Y.C. Chao T.K. Chang C.C. Yo Y.T. Yu M.H. Lai H.C. Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells PLoS One 8 2013 e74538
17 Karakas D. Cevatemre B. Aztopal N. Ari F. Yilmaz V.T. Ulukaya E. Addition of niclosamide to palladium (II) saccharinate complex of terpyridine results in enhanced cytotoxic activity inducing apoptosis on cancer stem cells of breast cancer Bioorg. Med. Chem. 23 2015 5580 5586 26234907
18 Pal S.K. Childs B.H. Pegram M. Triple negative breast cancer: unmet medical needs Breast Cancer Res. Treat. 125 2011 627 636 21161370
19 Yin L. Gao Y. Zhang X. Wang J. Ding D. Zhang Y. Zhang J. Chen H. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling Oncotarget 7 2016 42126 42138 27363012
20 Liu J. Chen X. Ward T. Pegram M. Shen K. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer Tumour Biol. 37 2016 9825 9835 26810188
21 Holmes D. A disease of growth Nature 521 2015 S2 S3 25970455
22 Barker N. Clevers H. Mining the Wnt pathway for cancer therapeutics Nat. Rev. Drug Discov. 5 2006 997 1014 17139285
23 Chen M.Y. Wang J.B. Lu J.Y. Bond M.C. Ren X.R. Lyerly H.K. Barak L.S. Chen W. The anti-helminthic Niclosamide inhibits Wnt/Frizzled1 signaling Biochemistry 48 2009 10267 10274 19772353
24 Osada T. Chen M.Y. Yang X.Y. Spasojevic I. Vandeusen J.B. Hsu D. Clary B.M. Clay T.M. Chen W. Morse M.A. Lyerly H.K. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations Cancer Res. 71 2011 4172 4182 21531761
25 Sack U. Walther W. Scudiero D. Selby M. Kobelt D. Lemm M. Fichtner I. Schlag Peter M. Shoemaker Robert H. Stein U. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer J. Natl. Cancer Inst. 103 2011 1018 1036 21685359
26 Suliman M.A. Zhang Z. Na H. Ribeiro A.L. Zhang Y. Niang B. Hamid A.S. Zhang H. Xu L. Zuo Y. Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family Int. J. Mol. Med. 38 2016 776 784 27460529
27 Ostrom Q.T. Gittleman H. Liao P. Rouse C. Chen Y. Dowling J. Wolinsky Y. Kruchko C. Barnholtz-Sloan J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011 Neuro-Oncology 16 Suppl. 4 2014 iv1 i63 25304271
28 Zeng T. Cui D. Gao L. Glioma: an overview of current classifications, characteristics, molecular biology and target therapies Front. Biosci. 20 2015 1104 1115 (Landmark edition)
29 Wieland A. Trageser D. Gogolok S. Reinartz R. Hofer H. Keller M. Leinhaas A. Schelle R. Normann S. Klaas L. Waha A. Koch P. Fimmers R. Pietsch T. Yachnis A.T. Pincus D.W. Steindler D.A. Brustle O. Simon M. Glas M. Scheffler B. Anticancer effects of niclosamide in human glioblastoma Clin. Cancer Res. 19 2013 4124 4136 23908450
30 Siegel R.L. Miller K.D. Jemal A. Cancer statistics, 2015 CA Cancer J. Clin. 65 2015 5 29 25559415
31 Li R. You S. Hu Z. Chen Z.G. Sica G.L. Khuri F.R. Curran W.J. Shin D.M. Deng X. Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer PLoS One 8 2013 e74670
32 Bigas A. Robert-Moreno A. Espinosa L. The Notch pathway in the developing hematopoietic system Int. J. Dev. Biol. 54 2010 1175 1188 20711994
33 Wang A.M. Ku H.H. Liang Y.C. Chen Y.C. Hwu Y.M. Yeh T.S. The autonomous Notch signal pathway is activated by Baicalin and Baicalein but is suppressed by Niclosamide in K562 cells J. Cell. Biochem. 106 2009 682 692 19160421
34 Jin Y. Lu Z. Ding K. Li J. Du X. Chen C. Sun X. Wu Y. Zhou J. Pan J. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species Cancer Res. 70 2010 2516 2527 20215516
35 Jin B. Wang C. Li J. Du X. Ding K. Pan J. Anthelmintic niclosamide disrupts the interplay of p65 and FOXM1/beta-catenin and eradicates leukemia stem cells in chronic myelogenous leukemia Clin. Cancer Res. 23 2017 789 803 27492973
36 Gridelli C. Maione P. Bareschino M.A. Schettino C. Sacco P.C. Ambrosio R. Barbato V. Falanga M. Rossi A. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments Anticancer Res. 30 2010 1301 1310 20530444
37 Li R. Hu Z. Sun S.Y. Chen Z.G. Owonikoko T.K. Sica G.L. Ramalingam S.S. Curran W.J. Khuri F.R. Deng X. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer Mol. Cancer Ther. 12 2013 2200 2212 23894143
38 You S. Li R. Park D. Xie M. Sica G.L. Cao Y. Xiao Z.Q. Deng X. Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer Mol. Cancer Ther. 13 2014 606 616 24362463
39 Lee S.L. Son A.R. Ahn J. Song J.Y. Niclosamide enhances ROS-mediated cell death through c-Jun activation Biomed. Pharmacother. 68 2014 619 624 24750999
40 Ottaviani G. Jaffe N. The epidemiology of osteosarcoma Cancer Treat. Res. 152 2009 3 13 20213383
41 Liao Z. Nan G. Yan Z. Zeng L. Deng Y. Ye J. Zhang Z. Qiao M. Li R. Denduluri S. Wang J. Wei Q. Geng N. Zhao L. Lu S. Wang X. Zhou G. Luu H.H. Haydon R.C. He T.C. Wang Z. The anthelmintic drug Niclosamide inhibits the proliferative activity of human osteosarcoma cells by targeting multiple signal pathways Curr. Cancer Drug Targets 15 2015 726 738 26118906
42 Yo Y.-T. Lin Y.-W. Wang Y.-C. Balch C. Huang R.-L. Chan M.W.Y. Sytwu H.-K. Chen C.-K. Chang C.-C. Nephew K.P. Huang T. Yu M.-H. Lai H.-C. Growth inhibition of ovarian tumor？initiating cells by Niclosamide Mol. Cancer Ther. 11 2012 1703 1712 22576131
43 Walters Haygood C.L. Arend R.C. Gangrade A. Chettiar S. Regan N. Hassmann C.J. 2nd Li P.K. Hidalgo B. Straughn J.M. Jr. Buchsbaum D.J. Niclosamide analogs for treatment of ovarian cancer Int. J. Gynecol. Cancer 25 2015 1377 1385 26186072
44 Arend R.C. Londono-Joshi A.I. Samant R.S. Li Y. Conner M. Hidalgo B. Alvarez R.D. Landen C.N. Straughn J.M. Buchsbaum D.J. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer Gynecol. Oncol. 134 2014 112 120 24736023
45 King M.L. Lindberg M.E. Stodden G.R. Okuda H. Ebers S.D. Johnson A. Montag A. Lengyel E. MacLean Ii J.A. Hayashi K. WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer Oncogene 34 2015 3452 3462 25174399
46 Chandrasekar T. Yang J.C. Gao A.C. Evans C.P. Mechanisms of resistance in castration-resistant prostate cancer (CRPC) Trans. Androl. Urol. 4 2015 365 380
47 Tran C. Ouk S. Clegg N.J. Chen Y. Watson P.A. Arora V. Wongvipat J. Smith-Jones P.M. Yoo D. Kwon A. Wasielewska T. Welsbie D. Chen C.D. Higano C.S. Beer T.M. Hung D.T. Scher H.I. Jung M.E. Sawyers C.L. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790 (New York, N.Y.) 19359544
48 Crona D.J. Milowsky M.I. Whang Y.E. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance Clin. Pharmacol. Ther. 98 2015 582 589 26331358
49 Liu C. Lou W. Zhu Y. Nadiminty N. Schwartz C.T. Evans C.P. Gao A.C. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer Clin. Cancer Res. 20 2014 3198 3210 24740322
50 Liu C. Lou W. Armstrong C. Zhu Y. Evans C.P. Gao A.C. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via STAT3-AR axis inhibition Prostate 75 2015 1341 1353 25970160
51 Hu C.D. Choo R. Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure Front. Oncol. 5 2015 90 25927031
52 Ippolito J.E. Brandenburg M.W. Ge X. Crowley J.R. Kirmess K.M. Som A. D'Avignon D.A. Arbeit J.M. Achilefu S. Yarasheski K.E. Milbrandt J. Extracellular pH modulates neuroendocrine prostate cancer cell metabolism and susceptibility to the mitochondrial inhibitor Niclosamide PLoS One 11 2016 e0159675
53 Murai M. Oya M. Renal cell carcinoma: etiology, incidence and epidemiology Curr. Opin. Urol. 14 2004 229 233 15205579
54 Chen S.C. Kuo P.L. Bone Metastasis from Renal Cell Carcinoma Int. J. Mol. Sci. 17 2016 e987
55 Zhao J. He Q. Gong Z. Chen S. Cui L. Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/beta-catenin and inducing mitochondrial dysfunctions SpringerPlus 5 2016 1436 27652012
56 Fogel N. Tuberculosis: a disease without boundaries Tuberculosis 95 2015 527 531 (Edinburgh, Scotland) 26198113
57 Sun Z. Zhang Y. Antituberculosis activity of certain antifungal and antihelmintic drugs Tuber. Lung Dis. 79 1999 319 320 10707260
58 de Carvalho L.P.S. Darby C.M. Rhee K.Y. Nathan C. Nitazoxanide disrupts membrane potential and intrabacterial pH homeostasis of Mycobacterium tuberculosis ACS Med. Chem. Lett. 2 2011 849 854 22096616
59 Iacobino A. Piccaro G. Giannoni F. Mustazzolu A. Fattorini L. Mycobacterium tuberculosis is selectively killed by Rifampin and Rifapentine in hypoxia at neutral pH Antimicrob. Agents Chemother. 61 61 2017 16 e02296
60 Piccaro G. Giannoni F. Filippini P. Mustazzolu A. Fattorini L. Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions Antimicrob. Agents Chemother. 57 2013 1428 1433 23295931
61 Friebe S. van der Goot F.G. Burgi J. The Ins and Outs of Anthrax Toxin Toxins 8 3 2016 69 10.3390/toxins8030069
62 Zhu P.J. Hobson J.P. Southall N. Qiu C. Thomas C.J. Lu J. Inglese J. Zheng W. Leppla S.H. Bugge T.H. Austin C.P. Liu S. Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death Bioorg. Med. Chem. 17 2009 5139 5145 19540764
63 Cegelski L. Marshall G.R. Eldridge G.R. Hultgren S.J. The biology and future prospects of antivirulence therapies Nat. Rev. Microbiol. 6 2008 17 27 18079741
64 Imperi F. Massai F. Ramachandran Pillai C. Longo F. Zennaro E. Rampioni G. Visca P. Leoni L. New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing Antimicrob. Agents Chemother. 57 2013 996 1005 23254430
65 Benfield T. Espersen F. Frimodt-Moller N. Jensen A.G. Larsen A.R. Pallesen L.V. Skov R. Westh H. Skinhoj P. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000 Clin. Microbiol. Infect. 13 2007 257 263 17391379
66 Rajamuthiah R. Fuchs B.B. Conery A.L. Kim W. Jayamani E. Kwon B. Ausubel F.M. Mylonakis E. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus PLoS One 10 2015 e0124595
67 Lou Z. Sun Y. Rao Z. Current progress in antiviral strategies Trends Pharmacol. Sci. 35 2014 86 102 24439476
68 Wu C.J. Jan J.T. Chen C.M. Hsieh H.P. Hwang D.R. Liu H.W. Liu C.Y. Huang H.W. Chen S.C. Hong C.F. Lin R.K. Chao Y.S. Hsu J.T. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide Antimicrob. Agents Chemother. 48 2004 2693 2696 15215127
69 Jurgeit A. Moese S. Roulin P. Dorsch A. Lotzerich M. Lee W.M. Greber U.F. An RNA replication-center assay for high content image-based quantifications of human rhinovirus and coxsackievirus infections Virol. J. 7 2010 264 20937137
70 Jurgeit A. McDowell R. Moese S. Meldrum E. Schwendener R. Greber U.F. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects PLoS Pathog. 8 2012 e1002976
71 Staples J.E. Breiman R.F. Powers A.M. Chikungunya fever: an epidemiological review of a re-emerging infectious disease Clin. Infect. Dis. 49 2009 942 948 19663604
72 Wang Y.M. Lu J.W. Lin C.C. Chin Y.F. Wu T.Y. Lin L.I. Lai Z.Z. Kuo S.C. Ho Y.J. Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission Antivir. Res. 135 2016 81 90 27742486
73 Heymann D.L. Hodgson A. Sall A.A. Freedman D.O. Staples J.E. Althabe F. Baruah K. Mahmud G. Kandun N. Vasconcelos P.F. Bino S. Menon K.U. Zika virus and microcephaly: why is this situation a PHEIC? Lancet 387 2016 719 721 (London, England) 26876373
74 Xu M. Lee E.M. Wen Z. Cheng Y. Huang W.K. Qian X. Tcw J. Kouznetsova J. Ogden S.C. Hammack C. Jacob F. Nguyen H.N. Itkin M. Hanna C. Shinn P. Allen C. Michael S.G. Simeonov A. Huang W. Christian K.M. Goate A. Brennand K.J. Huang R. Xia M. Ming G.L. Zheng W. Song H. Tang H. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen Nat. Med. 22 2016 1101 1107 27571349
75 Kaur J. A comprehensive review on metabolic syndrome Cardiol. Res. Pract. 2014 2014 943162 24711954
76 Lonardo A. Ballestri S. Marchesini G. Angulo P. Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome Dig. Liver Dis. 47 2015 181 190 25739820
77 Jaacks L.M. Siegel K.R. Gujral U.P. Narayan K.M. Type 2 diabetes: a 21st century epidemic Best Pract. Res. Clin. Endocrinol. Metab. 30 2016 331 343 27432069
78 Fairweather I. Boray J.C. Fasciolicides: efficacy, actions, resistance and its management Vet. J. 158 1999 81 112 10489266
79 Tao H. Zhang Y. Zeng X. Shulman G.I. Jin S. Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice Nat. Med. 20 2014 1263 1269 25282357
80 Pham T. Dick T.B. Charlton M.R. Nonalcoholic Fatty Liver Disease and Liver Transplantation Clin. Liver Dis. 20 2016 403 417 27063277
81 Mederos Y.S.M. Storch U. Gudermann T. Mechanosensitive Gq/11 protein-coupled receptors mediate myogenic vasoconstriction Microcirculation 23 2016 621 625 27344060
82 Li S.L. Yan J. Zhang Y.Q. Zhen C.L. Liu M.Y. Jin J. Gao J.L. Xiao X.L. Shen X. Tai Y. Hu N. Zhang X.Z. Sun Z.J. Dong D.L. Niclosamide ethanolamine inhibits artery constriction Pharmacol. Res. 115 2016 78 86 27872020
83 Smarr M.M. Kannan K. Buck Louis G.M. Endocrine disrupting chemicals and endometriosis Fertil. Steril. 106 2016 959 966 27424048
84 Prather G.R. MacLean J.A. 2nd Shi M. Boadu D.K. Paquet M. Hayashi K. Niclosamide as a potential nonsteroidal therapy for endometriosis that preserves reproductive function in an experimental mouse model Biol. Reprod. 95 2016 1 11 27387869
85 Treede R.D. Jensen T.S. Campbell J.N. Cruccu G. Dostrovsky J.O. Griffin J.W. Hansson P. Hughes R. Nurmikko T. Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes Neurology 70 2008 1630 1635 18003941
86 Ai N. Wood R.D. Yang E. Welsh W.J. Niclosamide is a negative allosteric modulator of Group I Metabotropic Glutamate Receptors: implications for neuropathic pain Pharm. Res. 33 2016 3044 3056 27631130
87 Zhang Y.K. Huang Z.J. Liu S. Liu Y.P. Song A.A. Song X.J. WNT signaling underlies the pathogenesis of neuropathic pain in rodents J. Clin. Invest. 123 2013 2268 2286 23585476
88 Nogueira E. Gomes A. Preto A. Cavaco-Paulo A. Update on therapeutic spproaches for Rheumatoid Arthritis Curr. Med. Chem. 23 2016 2190 2203 27149868
89 Liang L. Huang M. Xiao Y. Zen S. Lao M. Zou Y. Shi M. Yang X. Xu H. Inhibitory effects of niclosamide on inflammation and migration of fibroblast-like synoviocytes from patients with rheumatoid arthritis Inflamm. Res. 64 2015 225 233 25708600
90 Huang M. Zeng S. Qiu Q. Xiao Y. Shi M. Zou Y. Yang X. Xu H. Liang L. Niclosamide induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes Int. Immunopharmacol. 31 2016 45 49 26703449
91 Im A. Hakim F.T. Pavletic S.Z. Novel targets in the treatment of chronic graft-versus-host disease Leukemia 31 2017 543 554 27899803
92 Morin F. Kavian N. Nicco C. Cerles O. Chereau C. Batteux F. Improvement of Sclerodermatous Graft-Versus-Host Disease in mice by Niclosamide J. Invest. Dermatol. 136 2016 2158 2167 27424318
93 Pattanaik D. Brown M. Postlethwaite B.C. Postlethwaite A.E. Pathogenesis of Systemic Sclerosis Front. Immunol. 6 2015 272 26106387
94 Morin F. Kavian N. Nicco C. Cerles O. Chereau C. Batteux F. Niclosamide prevents Systemic Sclerosis in a reactive oxygen species-induced mouse model J. Immunol. 197 2016 3018 3028 27613696
95 Bertrand F.E. Angus C.W. Partis W.J. Sigounas G. Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch Cell Cycle 11 2012 4344 4351 23032367
96 Collu G.M. Hidalgo-Sastre A. Brennan K. Wnt-Notch signalling crosstalk in development and disease Cell. Mol. Life Sci. 71 2014 3553 3567 24942883
97 Fragoso M.A. Patel A.K. Nakamura R.E. Yi H. Surapaneni K. Hackam A.S. The Wnt/β-catenin pathway cross-talks with STAT3 signaling to regulate survival of retinal pigment epithelium cells PLoS One 7 2012 e46892
98 Hassanian S.M. Ardeshirylajimi A. Dinarvand P. Rezaie A.R. Inorganic polyphosphate promotes cyclin D1 synthesis through activation of mTOR/Wnt/β-catenin signaling in endothelial cells J. Thromb. Haemost. 14 2016 2261 2273 27546592
99 Kay S.K. Harrington H.A. Shepherd S. Brennan K. Dale T. Osborne J.M. Gavaghan D.J. Byrne H.M. The role of the Hes1 crosstalk hub in Notch-Wnt interactions of the intestinal crypt PLoS Comput. Biol. 13 2017 e1005400
100 Nakamura T. Tsuchiya K. Watanabe M. Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision J. Gastroenterol. 42 2007 705 710 17876539
101 Mook R.A. Jr. Ren X.R. Wang J. Piao H. Barak L.S. Kim Lyerly H. Chen W. Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis Bioorg. Med. Chem. 25 2017 1804 1816 28233680
102 Yang W. de Villiers M.M. Effect of 4-sulphonato-calix[n]arenes and cyclodextrins on the solubilization of niclosamide, a poorly water soluble anthelmintic AAPS J. 7 2005 E241 E248 16146345
103 Andrews P. Thyssen J. Lorke D. The biology and toxicology of molluscicides, Bayluscide Pharmac. Ther. 19 1983 245 295 (Very limited pharmacokinetic data in humans exists)
104 Merschjohann K. Steverding D. In vitro trypanocidal activity of the anti-helminthic drug niclosamide Exp. Parasitol. 118 2008 637 640 18226810
105 Chang Y.-W. Yeh T.-K. Lin K.-T. Chen W.-C. Yao H.-T. Lan S.-J. Wu Y.-S. Hsieh H.-P. Chen C.-M. Chen C.-T. Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats Yaowu Shipin Fenxi 14 2006 329 333
106 Ye Y. Zhang X. Zhang T. Wang H. Wu B. Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique Drug Dev. Ind. Pharm. 41 2015 1416 1424 25204767
107 Lin C.K. Bai M.Y. Hu T.M. Wang Y.C. Chao T.K. Weng S.J. Huang R.L. Su P.H. Lai H.C. Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer Oncotarget 7 2016 8993 9006 26848771
108 Mook R.A. Jr. Wang J. Ren X.R. Chen M. Spasojevic I. Barak L.S. Lyerly H.K. Chen W. Structure-activity studies of Wnt/beta-catenin inhibition in the Niclosamide chemotype: identification of derivatives with improved drug exposure Bioorg. Med. Chem. 23 2015 5829 5838 26272032
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 공개 리포지터리에 출판본, post-print, 또는 pre-print를 셀프 아카이빙 하여 자유로운 이용이 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.